GlobeNewsWire
11 Jun 2026, 01:08 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
What the story claims
3 claims · each scored for market impact
Humacyte is pricing a public offering of approximately 47.6 million shares of common stock at $1.05 per share. — A large secondary offering typically creates immediate downward pressure on the stock price due to significant equity dilution.
-0.60The company expects to raise aggregate gross proceeds of $50 million from the offering. — Increasing the cash runway is positive for a commercial-stage biotech company's operational stability.
+0.30Proceeds will be used to fund the commercialization of Symvess, a BLA supplement filing for hemodialysis, and other pipeline development. — Directing capital toward product commercialization and regulatory filings supports long-term growth potential.
+0.20Which stocks this story touches
Continue reading
6 related stories
The company is conducting a public offering of common stock, which typically results in equity dilution for existing shareholders.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
GlobeNewsWire
1d ago
